Trulieve Cannabis is trading at $9.88 (-4.03%) amid cannabis-sector pressure linked to a procedural delay in federal rescheduling.
- No clear company-specific announcement explaining the October 16 decline surfaced in available reporting.
- A DEA judge kept proceedings paused while awaiting further responses; the DEA response is due October 21.
- Steep losses in major indexes may also weigh on shares. The supplied sector trend is up, making the prior-day consumer-staples rally a less relevant explanation.